ahlam1399
06-26-2015, 10:50 AM
BRIEF-Adocia and Lilly report positive Phase 1b results on post-meal effect of ultra-rapid BioChaperone Lispro
* An**unced completion of a Phase 1b clinical trial evaluating BioChaperone lispro, an ultra-rapid formulation of insulin Lispro licensed to Lillyhttp://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4796bd33/sc/14/mf.gif?resize=1%2C1
http://rc.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/rc/1/rc.img (http://rc.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/rc/1/rc.htm)
http://rc.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/rc/2/rc.img (http://rc.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/rc/2/rc.htm)
http://rc.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/rc/3/rc.img (http://rc.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/rc/3/rc.htm)
http://da.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/a2.img (http://da.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/a2.htm)
http://adchoice.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/ach.img (http://adchoice.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/ach.htm)http://pi.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/a2t.imghttp://pi2.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/a2t2.imghttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=QzbPbLB9fCg:uNmOfdZm15E:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=QzbPbLB9fCg:uNmOfdZm15E:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=QzbPbLB9fCg:uNmOfdZm15E:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=QzbPbLB9fCg:uNmOfdZm15E:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=QzbPbLB9fCg:uNmOfdZm15E:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/QzbPbLB9fCg
* An**unced completion of a Phase 1b clinical trial evaluating BioChaperone lispro, an ultra-rapid formulation of insulin Lispro licensed to Lillyhttp://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4796bd33/sc/14/mf.gif?resize=1%2C1
http://rc.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/rc/1/rc.img (http://rc.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/rc/1/rc.htm)
http://rc.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/rc/2/rc.img (http://rc.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/rc/2/rc.htm)
http://rc.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/rc/3/rc.img (http://rc.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/rc/3/rc.htm)
http://da.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/a2.img (http://da.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/a2.htm)
http://adchoice.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/ach.img (http://adchoice.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/ach.htm)http://pi.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/a2t.imghttp://pi2.feedsportal.com/r/232767362891/u/49/f/654213/c/35217/s/4796bd33/sc/14/a2t2.imghttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=QzbPbLB9fCg:uNmOfdZm15E:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=QzbPbLB9fCg:uNmOfdZm15E:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=QzbPbLB9fCg:uNmOfdZm15E:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=QzbPbLB9fCg:uNmOfdZm15E:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=QzbPbLB9fCg:uNmOfdZm15E:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/QzbPbLB9fCg